Zenagamtide (international name), NNC0487-0111
An investigational peptide that switches on both GLP-1 and amylin receptors from a single molecule. Like other GLP-1 drugs it curbs appetite, and the amylin action adds fullness; it is being tested as a weekly injection and as a daily tablet.
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
Trial: tested in people, with the result.
Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
Amycretin, now named zenagamtide, is a single 68-amino-acid peptide that switches on GLP-1 receptors, which curb appetite and slow stomach emptying, and amylin receptors, which signal fullness after meals; in cell tests it also switched on calcitonin receptors. The same fatty side chain as semaglutide binds it to albumin, a blood protein, giving a half-life of about 3.7 days. One molecule is being tested as a weekly injection and as a daily tablet.
TrialMainly from studies in people.
How much each receptor adds in people, and what years of calcitonin-receptor activation do to calcium and bone, aren’t known. No trial longer than 36 weeks has reported; phase 3 results are expected from 2028.
Dahl, Lancet 2025
Obesity, weekly injection: stepped up from 0.3 mg to 1.25, 5, 20 or 60 mg. Weight fell 22.0% on 20 mg vs a 1.9% gain on placebo at 36 weeks, and 24.3% on 60 mg vs a 1.1% loss.
Mora, Lancet 2026
Type 2 diabetes, 36 weeks: weekly injections of 0.4–40 mg, started at 0.2 mg and raised every 4 weeks, or daily tablets of 6, 25 or 50 mg, started at 1.5 mg. HbA1c fell up to 1.7 and 1.4 points.
Trial registry, 2026
Phase 3 (AMAZE): one of four weekly injection doses for 84 weeks, or one of five daily tablet doses for 76 weeks; the doses haven’t been disclosed.
Continuous, shown over 26 weeks
The ways Amycretin is most often run, each tagged with where it comes from.
Single US center, small groups. Weight fell 9.7% (1.25 mg, 20 weeks), 16.2% (5 mg, 28 weeks), 22.0% (20 mg) and 24.3% (60 mg, 36 weeks).
Started at 0.2 mg and raised every 4 weeks. HbA1c fell 0.9–1.7 points; Novo Nordisk reported weight loss of up to 14.5% vs 2.6% on placebo, if all had stayed on treatment.
Started at 1.5 mg and raised every 4 weeks. HbA1c fell 0.9, 1.3 and 1.4 points; Novo Nordisk reported weight loss of up to 10.1% vs 2.5% on placebo.
Novo Nordisk’s 2024 presentation reported 10.4% and 13.1% weight loss vs 1.1% on placebo; the top dose was reached only 2 weeks before the end.
Injections go under the skin once a week; tablets are swallowed once a day, and studies are testing how meal timing and water volume affect absorption.
No published guidance; no trial has reported a missed-dose rule.
Tablet phase 1: Novo Nordisk reported 13.1% weight loss on 100 mg a day vs 1.1% on placebo (small groups).
TrialInjection phase 1b/2a: weight fell 9.7% on 1.25 mg by week 20 and 16.2% on 5 mg by week 28, vs 2.0–2.3% gains on placebo.
TrialInjection phase 1b/2a: 22.0% on 20 mg vs a 1.9% gain on placebo. Type 2 diabetes phase 2: HbA1c down up to 1.7 points (injection) and 1.4 (tablet).
TrialStomach side effects, mainly nausea and vomiting (tablet diabetes trial: 26–47% vs 23% on placebo)
Rose with dose and were mostly mild to moderate. Trials started low and stepped up every 4 weeks.
Less appetite (40.5% after a single 0.3 mg injection in a 42-person study)
Expected from how it works; meals may need planning to keep protein and fluids up.
Serious side effects (diabetes trial: 18 of 224 on injections vs 3 of 37 on placebo; 7 of 156 on tablets vs none of 30)
No deaths. The abstracts don’t say which events occurred.
Severe belly pain that won’t go away, signs of allergy, a racing heart at rest or fainting, or dehydration (dizziness, very little urine). Get medical help.
The side effects people ask about most, answered one by one. Each answer says where it comes from.
Trial: reported in human studies. Precaution: a concern that follows from how it works or from a related drug, not measured. Not reported: studied in people and not reported. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
No product label covers amycretin, so these come from human studies and from precautions based on how it works. Most important first.
Trial: seen in human studies, or a group those studies left out. Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
Trial: from human studies. Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
Usually run on its own.
5 key published human studies, with how many people took part. Animal studies aren’t listed here.
Weight fell 22.0% on 20 mg vs a 1.9% gain on placebo and 24.3% on 60 mg vs a 1.1% loss at 36 weeks; stomach side effects were most common, and many withdrew early.
Dahl et al., Lancet 2025, PMID 40550231
In type 2 diabetes on metformin, HbA1c fell 0.9 (0.4 mg) to 1.7 points (40 mg), 0.8–1.6 more than on placebo; serious events were about 8% on drug and on placebo.
Mora et al., Lancet 2026, PMID 42532080
HbA1c fell 0.9, 1.3 and 1.4 points, 0.5–1.1 more than on placebo; stomach side effects in 26–47% vs 23%.
Mora et al., Lancet 2026, PMID 42532079
Side effects in 62% of participants, all mild or moderate and rising with dose; about half of the events were stomach-related. Drug levels rose in proportion to dose.
Gasiorek et al., Lancet 2025, PMID 40550229
Drug levels with mild to severe kidney impairment or dialysis-dependent kidney failure were similar to normal (half-life 88 hours); no dose change judged necessary.
Oldenburg et al., Diabetes Obes Metab 2026, PMID 42443140
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
AMAZE 1: one of four weekly injection doses vs placebo for 84 weeks in about 1,150 adults with obesity: weight change
Recruiting since February 2026; completion expected August 2029
AMAZE 9: one of five daily tablet doses vs placebo for 76 weeks in about 950 adults with obesity: weight change
Recruiting since August 2026; completion expected August 2028
AMAZE 7: weekly injections vs semaglutide for 84 weeks in about 650 adults with obesity: weight change
Recruiting since September 2026; completion expected October 2028
HF-POLARIS: weekly injections vs placebo in about 5,610 adults with obesity and heart failure with preserved or mildly reduced pumping: heart deaths and heart failure events
Recruiting since May 2026; results expected in the second half of 2029
AMBIENCE: weekly injections vs placebo in about 8,500 adults with overweight or obesity and artery disease: heart attacks, strokes, heart deaths and heart failure events
Not yet recruiting (posted October 6, 2026); main results expected September 2030
Every compound’s registered trials: trials under way.
Published human data cover about 270 people in phase 1 studies of up to 36 weeks (injections and tablets), 448 adults with type 2 diabetes in a 36-week phase 2 trial, and 42 in a kidney study. Several weight results come only from company presentations, no obesity trial longer than 36 weeks has reported, and phase 3 results are expected from 2028. Long-term safety, calcitonin-receptor effects and products outside trials are unstudied.
Every compound side by side: the half-life chart and the storage chart.
Every compound’s numbers: the identifiers table.
No approved product. Trials use weekly injections and once-daily tablets, and tablet studies are testing how meal timing and water affect absorption. It isn’t commonly sold as a research peptide; anything sold has no regulated standard for identity, purity or sterility.
An investigational peptide that switches on both GLP-1 and amylin receptors from a single molecule. Like other GLP-1 drugs it curbs appetite, and the amylin action adds fullness; it is being tested as a weekly injection and as a daily tablet.
Amycretin, now named zenagamtide, is a single 68-amino-acid peptide that switches on GLP-1 receptors, which curb appetite and slow stomach emptying, and amylin receptors, which signal fullness after meals; in cell tests it also switched on calcitonin receptors. The same fatty side chain as semaglutide binds it to albumin, a blood protein, giving a half-life of about 3.7 days. One molecule is being tested as a weekly injection and as a daily tablet. How much each receptor adds in people, and what years of calcitonin-receptor activation do to calcium and bone, aren’t known. No trial longer than 36 weeks has reported; phase 3 results are expected from 2028.
Not approved anywhere. Novo Nordisk began the AMAZE phase 3 weight program with weekly injections in February 2026, then added a heart failure outcomes trial, comparisons with semaglutide and, from August 2026, tablet trials; first phase 3 results are expected in 2028. Never nominated for FDA’s 503A or 503B bulk lists (503A list updated May 14, 2026), and it isn’t part of any approved drug, so it doesn’t qualify for US compounding.
From human studies (Dahl, Lancet 2025): Obesity, weekly injection: stepped up from 0.3 mg to 1.25, 5, 20 or 60 mg. Weight fell 22.0% on 20 mg vs a 1.9% gain on placebo at 36 weeks, and 24.3% on 60 mg vs a 1.1% loss. Type 2 diabetes, 36 weeks: weekly injections of 0.4–40 mg, started at 0.2 mg and raised every 4 weeks, or daily tablets of 6, 25 or 50 mg, started at 1.5 mg. HbA1c fell up to 1.7 and 1.4 points (Mora, Lancet 2026). These are the amounts sources reference, not recommendations.
Injected under the skin once a week, or swallowed as a tablet once a day; both start low and step up, every 4 weeks in phase 2. It isn’t sold: it’s available only in clinical trials.
No product label covers amycretin, so these come from human studies and from precautions based on how it works. History of medullary thyroid cancer or MEN 2: Approved GLP-1 drugs are ruled out for this group because of thyroid C-cell tumors in rodents; no such data exist for amycretin. MEN 2 is an inherited tumor syndrome. Calcium or parathyroid disorders: The injection trial excluded abnormal calcium or parathyroid hormone, low vitamin D and high calcitonin. Amycretin also switches on calcitonin receptors, which help control calcium and bone. Raised pancreatic enzymes or past pancreatitis: The injection trial excluded amylase or lipase at twice the normal limit or more. Pancreatitis, sometimes fatal, is a listed risk of approved GLP-1 drugs such as semaglutide. The “Who should avoid it” section lists 3 more groups.
About 88 hours (3.7 days), measured in human studies. After a single 0.3 mg injection under the skin in 14 adults with normal kidney function; 94–113 hours with kidney impairment. Levels peaked about 2 days after the dose.
Before mixing: No label or published storage data; trial supplies are handled by the sponsor. After mixing: Not applicable: no product is sold outside trials. This is common practice; no product label covers it.
Probably. Not named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
Yes. The human studies section lists 5 published studies. The largest, from 2026, included 262 people. In type 2 diabetes on metformin, HbA1c fell 0.9 (0.4 mg) to 1.7 points (40 mg), 0.8–1.6 more than on placebo; serious events were about 8% on drug and on placebo.
Trial 36 weeks: the phase 1b/2a injection trial (125 adults) and the phase 2 diabetes trial (448 adults). Phase 3 trials run 52–84 weeks, longer for heart outcomes.
Trial The same molecule is tested as a weekly injection under the skin and a once-daily tablet; tablet studies are checking how food, meal timing and water affect absorption.
Precaution No data. Heavy drinking can itself cause pancreatitis, a listed risk of approved GLP-1 drugs.
Precaution It already acts on the GLP-1 receptor, so adding semaglutide or tirzepatide would double up; trials exclude people on GLP-1 drugs. A switching study from semaglutide is planned.
Trial No label or overdose data. Weekly injections up to 60 mg and daily tablets up to 100 mg were tested, mainly causing stomach side effects. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
For the protocol details
For how it works, who should avoid it and the limits of the evidence
For uses, the side-effect questions, special situations, trials, identifiers and status outside the US